Insulet Co. (NASDAQ:PODD) Shares Bought by Mackenzie Financial Corp

Mackenzie Financial Corp increased its stake in Insulet Co. (NASDAQ:PODD) by 25.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,029 shares of the medical instruments supplier’s stock after purchasing an additional 1,428 shares during the quarter. Mackenzie Financial Corp’s holdings in Insulet were worth $1,525,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PODD. Consolidated Portfolio Review Corp grew its stake in shares of Insulet by 1.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock valued at $806,000 after buying an additional 57 shares in the last quarter. New York Life Investment Management LLC boosted its position in shares of Insulet by 0.8% in the third quarter. New York Life Investment Management LLC now owns 10,035 shares of the medical instruments supplier’s stock valued at $1,600,000 after acquiring an additional 82 shares during the period. Allworth Financial LP raised its stake in shares of Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Insulet by 1.3% in the third quarter. Daiwa Securities Group Inc. now owns 7,316 shares of the medical instruments supplier’s stock worth $1,167,000 after purchasing an additional 93 shares during the period. Finally, KB Financial Partners LLC lifted its position in Insulet by 45.4% in the third quarter. KB Financial Partners LLC now owns 317 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 99 shares during the period.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Piper Sandler cut their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. JPMorgan Chase & Co. lifted their price target on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Barclays lowered their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Finally, Stifel Nicolaus lifted their price objective on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $243.21.

Insulet Trading Up 1.7 %

NASDAQ:PODD opened at $167.27 on Wednesday. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The stock has a market capitalization of $11.71 billion, a PE ratio of 57.48, a price-to-earnings-growth ratio of 2.96 and a beta of 0.98. The business’s 50-day simple moving average is $172.96 and its 200-day simple moving average is $179.44.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. The firm had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 EPS. Sell-side analysts expect that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.